SensiBileSensiBile is developing a point of care test to detect the quality of donor organs before transplantation.
Our test will enable transplant surgeons to avoid the use of poor quality livers, reducing biliary complications post-transplantation and providing a rationale platform for therapeutic interventions, thus saving lives and money.
The SensiBile team gained an ICURe NxNQ award in 2021, for global travel to conduct focused market validation activities.
The ability to spend dedicated time on customer discovery was a key output of the award and dramatically changed the perspective of our proposed innovation.
The ICURe programme was essential for our project. In our customer validation journey we approached a total of 97 potential customers, which included final users, key opinion leaders, potential partners, investors, regulatory and reimbursement representatives, among many others. We visited manufacturing centres in UK, Spain, Germany and Austria, attended online conferences and established partnerships that are still relevant in a daily basis.
The ICURe was crucial to engage with out main customer segment (the healthcare community), that confirmed there is a clear unmet need in the liver transplant field and that our approach offers a unique solution.
First tests and Lean Launch NxNW program
ICURe NxNW program
Scottish Enterprise HGSP funding, MRC-Confidence in concept funding. We Are Pioneer Group support; Converge kickstart challenge runner up
What companies had to say about the ICURe programme?
Co-Founder & CEO
Our mission is to provide a reliable, quantitative test to transplant surgeons, to define the quality of the donor organs before transplantation.We focus on donor livers prior-to-transplantation, but we aim to offer a multi-organ approach with pre and post-transplantation tests that will provide a comprehensive overview of organ quality.
We aim to revolutionize organ transplantation as we know it, saving lives, empowering transplant surgeons and minimizing the costs for the healthcare system.